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The accumulation of soluble and insoluble amyloid-β (Aβ) in the brain indicates failure of
elimination of Aβ from the brain with age and Alzheimer’s disease (AD). There is a variety of
mechanisms for elimination of Aβ from the brain. They include the action of microglia and
enzymes together with receptor-mediated absorption of Aβ into the blood and periarterial
lymphatic drainage of Aβ. Although the brain possesses no conventional lymphatics,
experimental studies have shown that fluid and solutes, such as Aβ, are eliminated from
the brain along 100 nm wide basement membranes in the walls of cerebral capillaries
and arteries. This lymphatic drainage pathway is reflected in the deposition of Aβ in
the walls of human arteries with age and AD as cerebral amyloid angiopathy (CAA).
Initially, Aβ diffuses through the extracellular spaces of gray matter in the brain and then
enters basement membranes in capillaries and arteries to flow out of the brain. Although
diffusion through the extracellular spaces of the brain has been well characterized, the
exact mechanism whereby perivascular elimination of Aβ occurs has not been resolved.
Here we use a computational model to describe the process of periarterial drainage
in the context of diffusion in the brain, demonstrating that periarterial drainage along
basement membranes is very rapid compared with diffusion. Our results are a validation
of experimental data and are significant in the context of failure of periarterial drainage
as a mechanism underlying the pathogenesis of AD as well as complications associated
with its immunotherapy.
Keywords: Alzheimer’s disease, brain, cerebral amyloid angiopathy, dextran, diffusion, lymphatic drainage,
perivascular drainage, simulation model
1. INTRODUCTION
Alzheimer’s disease (AD) is characterized pathologically by the accumulation of soluble and
insoluble amyloid-β (Aβ) in the extracellular spaces of the brain and tau-related neurofibrillary
tangles within neurons (Duyckaerts and Dickinson, 2011). Insoluble Aβ forms plaques within
cerebral gray matter and also accumulates within the walls of cerebral capillaries and arteries
as cerebral amyloid angiopathy (CAA; Weller et al., 2008). The increased levels of both soluble
and insoluble Aβ in the brain suggest that failure of elimination of Aβ is a significant factor
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in the pathogenesis of AD (Carare et al., 2013;Weller et al., 2015).
There is a variety of known mechanisms for the elimination of
Aβ from the brain, including degradation of insoluble plaques of
Aβ by microglia and the degradation of Aβ by enzymes such as
neprilysin (Miners et al., 2011). Aβ is absorbed into the blood by
receptor-mediated mechanisms (Zlokovic, 2004), passes into the
cerebrospinal fluid (CSF) (Iliff et al., 2012, 2013) and also drains
out of the brain along the pericapillary and periarterial lymphatic
drainage pathways (Carare et al., 2013). There is evidence for
failure of several mechanisms of elimination of Aβ with age and
in AD including failure of lymphatic drainage (Carare et al.,
2013).
The brain does not possess the conventional lymphatic
drainage vessels that are present in most organs of the body.
Furthermore, although Aβ is produced by most cells in the body,
there is no apparent failure of elimination of soluble Aβ in most
organs except the brain. Despite the lack of defined lymphatic
vessels, there is a well-developed and efficient lymphatic drainage
of interstitial fluid ISF and soluble metabolites, including Aβ ,
from the brain (Szentistvanyi et al., 1984; Carare et al., 2008,
2013) but lymphatic drainage is impaired with age (Hawkes et al.,
2011; Weller et al., 2015). Experimental studies have shown that
when soluble tracers including Aβ are injected into cerebral
gray matter, they initially diffuse through the extracellular spaces,
enter basement membranes around cerebral capillaries and then
flow out of the brain along basement membranes between
smooth muscle cells in the tunica media of cerebral arteries
(Carare et al., 2008; Hawkes et al., 2011). Such periarterial
lymphatic drainage is rapid and when drainage of tracer is
complete, the route appears to be outlined by perivascular
macrophages that have imbibed tracer during its passage along
the periarterial lymphatic drainage pathway (Cserr and Ostrach,
1974; Cserr et al., 1977, 1981; Carare et al., 2008).
Soluble metabolites, produced by cells within the central
nervous system (CNS), begin their journey out of the brain by
entering interstitial fluid ISF and passing through the narrow ECS
in the brain before entering the perivascular drainage pathways
within basement membranes (100–150 nm thick) in the walls
of capillaries and arteries (Carare et al., 2008). This transport
mechanism is mirrored by the deposition of Aβ in basement
membranes in AD. The narrow gaps that separate cells in the
gray matter of the CNS form the ECS that are in direct continuity
with basement membranes of capillaries (Figure 1). Recent data
demonstrate that the ECS in the cerebral cortex is 38–68 nm
wide, which is significantly larger than the traditional value of
20 nm observed by electron microscopy (Thorne and Nicholson,
2006). Functionally, the ECS provides a pathway for diffusion and
exchange of ions and molecules between cells. In the brain, the
space between the cells is occupied by ISF derived from the blood
and CSF. Water generated as a result of oxidation of glucose to
CO2 and water could provide a 10% contribution to the total
volume of ISF (Abbott, 2004). A large fraction of ISF may be
derived from the blood through the capillary endothelium, driven
by Na+-K+-ATPase, with water following passively (Abbott,
2004).
Diffusion of molecules through the extracellular spaces of
cerebral gray matter is well characterized. The most widely used
FIGURE 1 | Micrograph of cortical Wistar Kyoto rat capillary. The
cerebrovascular basement membrane is the electron dense area between the
four empty arrow heads. The extracellular matrix is the area between the filled
arrow heads. The * marks an area of continuity between the extracellular matrix
and the cerebrovascular basement membrane. Lu Capillary Lumen, Edc -
Endothelial cell, and Ast - Astrocyte end foot. TEM, 50,000x, scale bar 500 nm.
method for studying diffusion is the real-time iontophoretic
method TMA (tetramethylammonium) devised by Nicholson
and Phillips, demonstrating that molecules execute random
walks through the extracellular space (Nicholson et al., 2000).
However, there is a gap in our understanding of the dynamics
of periarterial drainage of ISF and solutes, including Aβ , out
of the brain and how these dynamics relate to diffusion.
Understanding such dynamics is important not only for
clarifying the pathogenesis of AD and designing therapies, but
also for characterizing drug delivery to the brain and spinal cord
(Carare et al., 2013).
In previous experiments, it has been shown that, following
injection into the central gray matter of the mouse brain,
4 kDa fluorescent tracer spreads diffusely through the brain
parenchyma and enters basement membranes of cerebral
capillaries and cerebral arteries (Carare et al., 2008).Within 5min
of the injection, tracer is present at the surface of the brain
(Carare et al., 2008). The question we seek to answer here is
whether progress of the tracer from the injection site to the
surface of the brain is by diffusion or by another mechanism
along capillary and periarterial pathways. In order to resolve this
question in the present paper, we use a computational model
to define the process of periarterial drainage in the context of
diffusion within the extracellular spaces of cerebral gray matter.
First, we construct a mathematical computational model that
encompasses both diffusion and periarterial lymphatic drainage
and second we simulate the movement of solutes of low
molecular weight, similar to Aβ , through the extracellular spaces
of gray matter in the brain. By these techniques, we demonstrate
that diffusion through the extracellular spaces cannot alone
account for the rapid movement of solutes toward the surface
of the brain, but, when coupled with periarterial drainage,
solutes reach the walls of arteries on the surface of the brain
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within the observed time-scale of 5min. While similar questions
have been addressed in the literature, our study is the first
to specifically address the issue of perivascular drainage along
basement membranes. Specifically, work by Groothuis et al.
(2007) emphasizes the difference in clearance rates of various
tracers, dependent on diffusion, convection, and transport across
the endothelium into the blood, but the time scales analyzed were
over several hours, whereas in our study we address the rapid
entry of solutes into the basement membranes. Our findings
help to clarify the dynamics of lymphatic drainage of the brain
that plays a significant role in the elimination of Aβ and its
failure in AD.
2. METHODS
All simulations are carried out using the “Transport of Diluted
Species” module in COMSOL Multiphysics 4.4 (build 248)
using a time-dependent solver over 32min. This period was
divided into 2min for the injection of molecules and 30min
observation time. The geometries used are a two-dimensional
(2D) coronal and a 2D sagittal section from the Allen Brain Atlas
(Mouse Brain Reference Atlas, Lein et al., 2007). The slices were
chosen according to the injection site in Carare et al. (2008)
(bregma 1 mm anterior, lateral + 1.5 mm, 2.5 mm deep) and
were estimated as slice 55 (coronal) and slice 14 (sagittal). Both
sections were simplified by homogenizing all gray and white
matter, i.e., defining one averaged material for all gray matter
and one averaged material for all white matter, where all sections
that are not listed as “gray” in the atlas were interpreted as
white matter. Figure 2 compares the slices as obtained from the
Allen Brain Atlas and the geometries used in the simulations.
The geometries were created using the MATLAB LiveLink for
COMSOL. For each slice two separate geometries (gray and
white matter) were created, which were combined into a single
geometry in COMSOL (Figure 2). To simulate the injection
needle a rectangle with a width of 50 µm and a length of 2.5 mm
was inserted 1.5 mm to the right of the vertical centre line in
the coronal slice and 5.5 mm from the front of the brain in the
sagittal slice. The geometry provides the basis for the creation of
a mesh of elements on which chemical species concentrations are
evaluated during the simulation.
2.1. Mesh Size and Time Stepping
Following the setup of the model simulation case A1 (refer to the
remainder of this section for implementation details) was used to
carry out a mesh convergence study on the coronal slice to ensure
that the choice of mesh resolution does not alter the results.
The mesh convergence study was based on the “Adaptive mesh
refinement” option in the COMSOL solver. This option adapts
the mesh size according to an error indicator ε, which in this case
was chosen as the root mean square of the derivative of dextran
concentration c in x and y and y and z direction in the coronal
FIGURE 2 | Geometry of the coronal and sagittal sections of a mouse brain used in the simulations. (A) Coronal slice as obtained from the Allen Institute for
Brain Science (Lein et al., 2007). (B) The homogenized simulation geometry of the coronal slice has a width of 8mm and a height of 5.5mm. The thin black rectangle
depicts the position of the injection needle, with the tip at position (5.7, 2.8mm). (C) Sagittal slice as obtained from the Allen Institute for Brain Science (Lein et al.,
2007). (D) The homogenized simulation geometry of the sagittal slice has a length of 13.7mm and a height of 5.5mm. The black rectangle depicts the position of the
injection needle, with the tip at position (6.1, 3.9mm). One material type is defined for all gray matter (gray) and one material type is defined for all white matter (white).
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and sagittal slice, respectively. For the coronal slice we define
εcoronal =
√(
dc
dx
)2
+
(
dc
dy
)2
(1)
and analogously for the sagittal slice. The “adaptive mesh
refinement” option has the advantage of automatically refining
regions where ε is high. The convergence criterion for evaluating
the meshes that were created by COMSOL the concentration
c of dextran in the ECS at three different locations at 5min
after the injection was used (Figure 3). The concentration was
dedimensionalized using the injection concentration of 0.33mM.
For the coronal slice a mesh containing 47,342 triangular mesh
elements was deemed optimal, while for the sagittal the optimal
mesh contains 294,967 triangular mesh elements. Note that the
sagittal slice is much larger than the coronal slice and therefore it
contains more mesh elements.
The optimal time step for the simulations was determined
using the Courant-Friedrichs-Lewy (CFL) condition, where the
Courant number
C =
u ·1t
1x
(2)
FIGURE 3 | Dimensionless dextran concentration c over the number of
mesh elements at 5min after the injection for three different locations.
(A) Mesh convergence study for the coronal slice, p1 = (5.7, 2.8mm), p2 =
(6.0, 2.8mm), p3 = (6.3, 2.8mm). The dashed vertical line indicates the
optimal mesh, which consists of 47,342 triangular mesh elements. At this size
c is fully converged for p3, but not for p1 and p2, where c oscillates around a
value similar to that at the chosen mesh size with the magnitude of oscillations
much smaller than the detection limit. (B) Mesh convergence study for the
sagittal slice. (B) Mesh convergence study for the sagittal slice, p1 = (6.1,
3.9mm), p2 = (6.4, 3.9mm), p3 = (6.7, 3.9mm). The optimal mesh was found
at a size of 294,967, where all concentration values have reached
convergence.
is smaller than some maximum number Cmax, chosen to be 1.
Then 1x represents the side length of the smallest triangular
mesh element and u represents the flow velocity. With 1x =
2.36 · 10−6m, u = 8.33 · 10−6ms−1, and choosing C = 0.5 we
obtain1t = 0.14s.
2.2. Diffusion and Bulk Flow
The transport of a diluted substance such as dextran via diffusion
and convective forces can be described by writing
∂c
∂t
= D∗∇2c− (u · ∇)c− kc, (3)
where c is the concentration of the substance within the ECS
in mol l−1 or M, u is the convective velocity vector in m s−1,
k is the uptake rate in s−1 and D∗ is the effective diffusion
coefficient in m2 s−1 (Nicholson, 2001). It is important to note
at this point that although the simulations are carried out in a
2D plane the concentration units are the same as for a three-
dimensional (3D) simulation. COMSOL implicitly assumes a
third dimension in the out of plane direction with a unit depth
of 1m for all 2D simulations. The effective diffusion coefficient
D∗ of a substance is lower than its diffusion coefficient D in a
free medium due to the tortuosity of the diffusion pathways in
the medium. The tortuosity of a medium is described via the
parameter λ and we obtain D∗ by writing D∗ = D/λ2. The
factors contributing to the tortuosity and the techniques used to
study the diffusion coefficients in the ECS have been discussed by
Syková and Nicholson (2008).
2.2.1. Boundary Conditions
The boundary conditions at the boundaries of the brain with the
needle, with the exception of the tip of the needle, as well as the
outer boundaries of the brain are defined as “No Flux,” which
means that no mass flows across the boundary
− n ·
(
cu− D∗∇c
)
= 0. (4)
The boundary condition at the tip of the needle is defined as
“Inflow,” where the concentration is set to a fixed value such that
c = c0. (5)
Equations (3)–(5) form the governing equations of the system.
2.2.2. Parameters
All simulation parameters are summarized in Table 1. The
following paragraphs detail the derivation and source references
for each of those parameters for dextran.
As discussed above the mouse brain is simplified by
homogenizing all gray and white matter (that is considering
all gray and white matter as one). Accordingly, we have
homogenized the tortuosity λ values reported in Syková and
Nicholson (2008). Because of the sparsity of values for the mouse
brain and the similarity of mouse and rat values we have used rat
values where necessary. Note that tortuosity for the gray matter is
isotropic, while tortuosity in the white matter is anisotropic due
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TABLE 1 | Solute drainage parameters used in the simulations.
Parameter Value Source
Bulk flow velocity in white
matter u
1.75× 10−7ms−1 Rosenberg et al., 1980
Apparent perivascular
drainage velocity ub
8.33× 10−6ms−1 Carare et al., 2008
Diffusion coefficent D* 8.7× 10−11m2s−1 Nicholson and Tao, 1993
Uptake rate kb 2.5× 10
−4 s−1 Ito et al., 2013
to the directionality of the fiber tracts, such that D∗ becomes a
matrix
D∗ =
(
D/λ2x 0
0 D/λ2y
)
. (6)
The tortuosity values used in this study are summarized in
Table 2. The effective diffusion coefficient D∗ for dextran (3 kDa)
was obtained directly from Nicholson and Tao (1993), which has
been measured at 34 ◦C. To correct this to a temperature of 37 ◦C
we use
D37 =
T37
T20
µ20
µ37
D20, (7)
where T37 and T20 are temperatures in K, µ37, and µ20 are the
dynamic viscosities andD37 andD20 are the diffusion coefficients
at temperatures T37 and T20, respectively. Using this equation
and the dynamic viscosity of water (Philippoff, 1957) at the given
temperatures we can correct our diffusion coefficient to D∗ =
8.7× 10−11m2 s−1.
The importance of bulk flow along the white matter in the
ECS is not clear and has been discussed in the literature (see
for example Rosenberg et al., 1980; Ohata and Marmarou, 1992;
Abbott, 2004). According to Syková and Nicholson (2008) the
influence of bulk flow on short-term and near-distance diffusion
is small, whereas it could have a significant impact over long
distances and times. The influence of bulk flow, however, is hard
to quantify. In this study we therefore implement simulations for
both cases – with and without bulk flow along the white matter.
Where a simulation includes bulk flow along the white matter we
adopt the findings fromRosenberg et al. (1980) and assume a bulk
flow velocity of |u| = 1.75× 10−7ms−1 following the direction
of the fibers. We recognize that this value has been measured in
the cat rather than the mouse, where the white matter is likely to
be organized differently. However, to the best of our knowledge
no other data on bulk flow along white matter are available in
the literature and therefore we use the Rosenberg value. Recently,
Iliff et al. (2012, 2013) have suggested a convective bulk flow
pathway from arteries to veins in the ECS through the gray
matter. However, this effect has not been quantified and has
therefore not been included in this study.
Finally, the uptake term kc needs to be determined. The
total uptake rate k determines the time scale at which tracers
are eliminated from the ECS. Normally, this uptake rate
encompasses two different mechanisms, which need to be
considered separately. The first mechanism is the degradation
TABLE 2 | Tortuosity values for gray and white matter as obtained and
summarized from (Syková and Nicholson, 2008).
Region λx λy λz
Gray matter 1.60 1.60 1.60
White matter 1.47 1.68 1.68
of solutes by enzymes or cells at rate kd. As this mechanism
is not relevant for dextran kd has been eliminated. The second
mechanism represents the transport of tracers across the blood-
brain barrier (BBB) into the blood (Deane et al., 2004) and the
transport into the perivascular drainage pathways within the
basement membrane at rate kb. Note here that while we are using
a first-order rate process to model the transport of tracers into
the basement membrane this is not treated as a loss process.
Instead, the term kbc appears as a source term in the equation
governing the perivascular drainage mechanism. Ito et al. (2013)
have measured both kd and kb for Aβ and we used their value
for kb = 2.5× 10
−4 s−1 for the uptake of dextran as we assume
that the rate of molecule transport into the basement membrane
is the same for Aβ and dextran. Furthermore, we assume that this
process captures all first-order rate processes such that k = kb.
As in Carare et al. (2008) 0.5 µl of 3 kDa dextran at a
concentration of 1 µg µl−1 was injected over a period of 2min.
To convert the units of concentration of dextran to molarity
M, as is required for the chosen type of boundary condition in
COMSOL, we calculate the molar mass of dextran by multiplying
its molecular weight with Avogadro’s constant. We can then
divide the concentration given in µg µl−1 by the molar mass and
obtain a molar concentration of c0 = 0.33mM for the injection.
The boundary condition (Equation 5) therefore becomes
c =
{
c0 t = 0–2min
0 t > 2min
. (8)
Additionally, one has to take into account the convective flow
generated by the injection of tracer into the brain. We have
conducted test simulations on the coronal slice using various
convective flow velocities. These tests show that velocities of
up 4.0× 10−6ms−1 (roughly half the perivascular drainage
velocity) have a negligible effect on the tracer distribution. As we
regard higher velocities than that too high given the time frame
of the injection we have omitted this initial convective flow for
the remaining simulations.
2.3. Perivascular Drainage
Molecules “switch” from being in the ECS to being in the
perivascular drainage pathways in the basement membranes
of cerebral arteries at rate kb, which can be modeled in
COMSOL using a “Reactions” node to account for production
and consumption of chemical species. If we call the concentration
of dextran in the ECS c and the concentration of dextran in the
basement membranes cb, then kb acts as a take-up coefficient
and the term −kbc is part of Equation (3), while the equations
for the transport of species in the basement membrane receive
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a source term sb = kbc. Note that although we use different
names for the concentrations of tracer in the ECS and the
basement membrane these concentrations both describe dextran,
but in different compartments. Note that in this representation
we are modeling the two phenomena—parenchymal diffusion
and perivascular convective flow—as two separate “layers” on the
geometry. This means that every point in space is at the same
parenchymal and perivascular.
As we assume that convective flow in the basement membrane
is the dominant transport process we eliminate diffusion by
setting the diffusion coefficient D∗
b
to the very small internal
parameter “eps” in COMSOL, which represents the machine
precision (it is not possible to set D∗
b
to 0 as this results in
a singular matrix). The governing equation in the basement
membrane is
∂cb
∂t
= D∗b∇
2cb − (ub · ∇)cb + sb. (9)
2.3.1. Boundary Conditions
The boundary conditions are the same as for the ECS part of the
simulation with the exception of the needle tip, which is changed
to “No Flux” (Equation 4).
2.3.2. Parameters
As the “production” of dextran in the basement membrane is
directly coupled to the “loss” of dextran from the ECS the only
parameter that remains to be determined is the perivascular
drainage velocity ub. As the lymphatic drainage pathways follow
the basement membranes inside the walls of all arteries in the
brain modeling these pathways explicitly and in detail is beyond
the scope of this paper. Instead we can utilize measurements
taken by Carare et al. (2008) about the distance dextran has
traveled within the basement membrane. Two statements on the
distance dextran has traveled can be found in Carare et al. (2008):
(a) Dextran was found at a maximum distance of 2.5 mm from
the injection site in the rostro-caudal direction after 5min, which
was measured by the number of 10 µm coronal slices from the
injection site that still contained dextran, and (b) the dextran
distribution had a mean radius of 785 µm. Tomodel the observed
perivascular drainage velocity we use statement (a) as statement
(b) coincides with the observations when simulating diffusion
only (see simulation case A1 in the Results section). This is valid
as after 5min the bulk of dextran is expected to still remain in the
ECS. We therefore assume that it is the process of perivascular
drainage that results in the observation of a maximum travel
distance of 2.5 mm at 5min. The easiest way of simulating a
transport process that transports tracers to the given distance
within the given time is by implementing its velocity as a vector
ub = (x, y) = (8.33× 10
−6ms−1, 0) in the coronal slice and
ub = (y, z) = (0, 8.33× 10
−6ms−1) in the sagittal slice.
This representation of the perivascular drainage pathways
and their geometries is notably extremely simplified. However, a
realistic representation could only be achieved through modeling
of the whole vascular tree in the brain. For the aim of this paper,
which is the comparison of the macroscopic phenomenon of
dextran reaching 2.5 mm in 5min to the effect of diffusion, our
representation was deemed sufficient. Foley et al. (2012) have also
measured convective flow velocity along perivascular pathways
and it is interesting to note that they have measured velocities of
one order of magnitude larger than our estimate. However, there
are significant differences between their study and Carare et al.
(2008), such as the use of nanoparticles whose molecular size is
much larger than that of 3 kDa dextran. Therefore, we use the
observation fromCarare et al. (2008) as our perivascular drainage
velocity estimate.
2.4. Simulation Cases
All simulation cases are listed in Table 3. The Péclet number Pe is
a dimensionless number to quantify the ratio of convective flow
and diffusion and is defined as
Pe =
LU
D
, (10)
where L is an appropriate length scale, U is velocity, and D is
the diffusion coefficient. Here we choose the height of the mouse
brain as the length scale. The Peclet number can be used to
TABLE 3 | Simulation cases used to determine the necessity of convective transport mechansims to explain perivascular drainage.
Case Diffusion Bulk flow velocity Perivascular drainage Uptake Pe
coefficient D* in white matter u velocity |ub| rate kb
A1 D* 0 0 0 0
A2 5 · D* 0 0 0 0
A3 10 · D* 0 0 0 0
B1 D* u 0 0 11.08 (u)
B2 D* 5 · u 0 0 55.38 (u)
B3 D* 10 · u 0 0 110.76 (u)
C1 D* u ub kb 527.22 (ub)
C2 D* u ub/2 kb 263.61 (ub)
C3 D* u ub/2 kb/10 263.61 (ub)
C4 5 · D* u ub/2 kb/10 105.44 (ub)
D* = 8.7× 10−11 m2 s−1, |u| = 1.75 × 10−7 ms−1, |ub = 8.33 ×10
−11 ms−1, kb = 2.5× 10
−4 s−1 (Table 1).
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determine the balance between diffusion and advection that is
required to obtain the expected results.
The goal of this paper is to show that diffusion alone is not
enough to explain perivascular drainage. First, in cases A and
B diffusion and bulk flow are considered as the only driving
forces of solute drainage in the brain. The parameters for case C1
were determined from the results of the experiments in Carare
et al. (2008), while the remaining simulation cases were designed
to test reduced parameters for perivascular drainage against an
elevated diffusion coefficient.
The simulation cases were set up to demonstrate that even
if the reported values for diffusion and perivascular drainage
have been under- or overestimated, respectively, diffusion alone
remains unable to explain the experimental results from Carare
et al. (2008). If in all of these simulation cases diffusion is unable
to account for the experimental results in Carare et al. (2008) then
we can claim with a high degree of confidence that a convective
transport mechanism such as perivascular drainage must exist.
3. RESULTS
To compare diffusion and perivascular drainage the maximum
distance a tracer has traveled from the injection site is measured
by calculating the largest distance between the injection site
and a point whose tracer concentration is at least 0.1% of
the injection concentration. This dextran detection criterion
has been established in pilot studies prior to Carare et al.
(2008). The distance is calculated using a Euclidean distance
measure
d =
√
(x2 − x1)2 + (y2 − y1)2, (11)
where d is the distance betweeen two points with the coordinates
(x1, y1) and (x2, y2).
3.1. Coronal Slice
The maximum distance for each of the simulation cases at
both 5 and 30min after the end of the injection is given in
Table 4. Supplementary Figures 1, 2 show different levels of the
TABLE 4 | Maximum spread of dextran in the coronal slice for each of the
simulation cases at 5 and 30min after the injection.
Case Maximum distance from Maximum distance from
injection site at 5 min (mm) injection site at 30 min (mm)
A1 0.76 1.35
A2 1.72 2.80
A3 2.20 3.38
B1 0.76 1.34
B2 0.74 1.41
B3 0.72 1.52
C1 2.46 2.46
C2 2.46 2.46
C3 0.76 2.46
C4 1.72 2.48
distribution of dextran above the detection limit of 0.1% of
the injection concentration. The dextran concentration is non-
dimensionalized using the minimum detection concentration.
Cases A1–3 consider only diffusion as the driving force of
solute transport. In none of the simulation cases does dextran
reach as far as is expected from the results in Carare et al. (2008).
If the actual diffusion coefficient is at least five times higher than
the expected diffusion coefficient dextran can reach the surface of
the brain within 30min, but most dextran remains in the ECS at
the injection site.
In cases B1–3 the effect of bulk flow is considered. Upon
comparing these cases to A1 no signifcant effect of bulk flow
along the white matter on solute transport is observed.
The effect of perivascular drainage is examined in cases C1–
4. Only in case C1 does dextran appear to reach the distance of
2.5 mm within 5min after the injection of dextran. However, the
contours are disconnected. To aid the explanation of this in the
discussion, Supplementary Figure 3 extends the first contour to
0.1, which represents a concentration of 0.01% of the injection
concentration. Cases C2–4 do not reach 2.5 mm within 5min. In
these cases diffusion appears to be the dominant process of solute
transport until 5min after the injection, when enough dextran
has entered the perivascular drainage pathways in the basement
membrane, while 30min after the injection we observe the same
results as for case C1.
In order to further analyse the distances dextran traveled in
the different simulation cases it is useful to study the maximum
distance dextran has traveled over time (Figure 4). Each of
the subfigures shows the results for all simulation cases in the
background in gray. Vertical dashed lines mark the time points
2min into the simulation where the injection ends and 5min
after the end of the injection, while the horizontal dashed line
marks the distance we expect dextran to have traveled at the
5min time point. The results show that the only simulation cases
reaching 2.5 mm are C1 and C2 and all simulation cases in
group C are faster than all other simulation cases. None of the
simulations in case group B reaches 2.5 mm at the end of the
simulation time (30min).
3.2. Sagittal Slice
The sagittal slice produces very similar results compared to
the results reported for the coronal slice. Table 5 shows the
maximimum distance dextran has traveled at the 5 and 30min
time points. It shows that case C1 is the only case in which
dextran spreads beyond 2.5 mm. In the coronal slice case C2 also
reached the 2.5 mmmark.
Supplementary Figure 4 shows the contour levels of dextran
concentration at 5min after the injection (analogously to S1).
Visual observation of these contour plots does not show dextran
reaching a 2.5 mm distance in case C1. To aid the explanation
of this observation a contour plot that includes the contour level
of 0.1 is given in Supplementary Figure 3. Case C2 appears to
reach around 2 mm. The results for the remaining cases are
analogous to the respective cases in the coronal slice. The same
holds for all cases in Supplementary Figure 5 (30min after the
injection).
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FIGURE 4 | Maximum distance dextran traveled for each simulation
over time (coronal). (A) The simulation cases A1–3 are highlighted against
the other simulation cases. Dextran does not reach the expected distance in
any of the simulation cases. It takes around 7.5min after the injection for
dextran to reach the 2.5mm point in case A3, where the diffusion coefficient is
increased by a factor of 10. (B) The simulation cases B1–3 are highlighted
against the other simulation cases. The results for each of these simulations
are very similar to case A1. (C) The simulation cases C1–4 are highlighted
against the other simulation cases. In cases C1 and C2 dextran reaches the
2.5mm point within 5m after the injection, while the remaining two cases take
up to 2m longer. Case C4 takes longest to reach 2.5mm and reaches it at the
same time as the fastest diffusion case (A3).
To aid the analysis of the results Figure 5 shows the maximum
distance dextran has traveled from the injection site at any time
during the simulation. For case groups A and B the results here
are very similar again to the results of the coronal slice. The
results for case group C are different. Case C1 gets an early spike
at around 1min after the end of the injection. This spike then
drops back to the diffusion level, but then increases again to the
required level before the 5min time point.
4. DISCUSSION
The results of this study demonstrate that diffusion alone
cannot account for the pattern of drainage of fluid and solutes
TABLE 5 | Maximum spread of dextran in the sagittal slice for each of the
simulation cases at 5 and 30min after the injection.
Case Maximum distance from Maximum distance from
injection site at 5 min (mm) injection site at 30 min (mm)
A1 0.79 1.28
A2 1.75 2.95
A3 2.28 3.54
B1 0.78 1.29
B2 0.80 1.43
B3 0.94 1.57
C1 7.75 8.49
C2 1.40 8.06
C3 0.76 7.83
C4 1.73 8.16
from the brain parenchyma. Our results show that complex
convective transport pathways exist in the brain for the clearance
of solutes produced during brain metabolism. The drainage
pathway, therefore, is partly dependent upon diffusion through
the ECS between cell processes in the brain parenchyma and
partly reliant upon a more rapid system of convective flow along
basement membranes within walls of cerebral capillaries and
arteries.
The results of Supplementary Figure 1match the results from
Carare et al. (2008). None of the simulations in case group A
(diffusion only) reach the 2.5 mm mark in 5min after the end of
the injection. Only case A3 gets close (2.2 mm) to the required
distance mark, but this assumes that the diffusion coefficient
reported in Nicholson and Tao (1993) is wrong by an order of
magnitude. In case A1 dextran reaches a distance of 0.76 mm,
which is close to the reported mean value of dextran distribution
of 0.79 mm in Carare et al. (2008). The results of case A2 do not
correlate with any of the results in Carare et al. (2008). At 30min
after the end of the injection (Supplementary Figure 2) both case
A2 and A3 have traveled beyond the 2.5 mm mark while case
A1 has not. This shows that the dextran found at the surface
of the brain at 30min after the end of the injection is a result
of a convective transport mechanism. Figure 4, which shows the
maximum distance dextran has traveled at any time compared to
the remaining cases, confirms these results and also shows that
the simulations from case group A can travel beyond the 2.5 mm
mark. This is due to diffusion acting in all directions, whereas
perivascular drainage is implemented to only act in the positive
x-direction and therefore encounters the boundary of the brain
at 2.46 mm.
For case group B the results presented in
Supplementary Figures 1, 2 and Figure 4 show that bulk
flow does not have a significant effect on solute drainage. All
three cases in this group match the results of case A1 very closely
for both time points and will therefore be omitted from the rest
of the discussion.
In case group C both cases C1 and C2 manage to reach
the distance mark of 2.5 mm within 5min. In case C1,
however, there are two separate disconnected sections of
dextran concentration above the detection limit. To explain
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FIGURE 5 | Maximum distance dextran traveled for each simulation
over time (sagittal). (A) The simulation cases A1–3 are highlighted against
the other simulation cases. Dextran does not reach the expected distance in
any of the simulation cases. It takes around 7.5min after the injection for
dextran to reach the 2.5mm point in case A3, where the diffusion coefficient is
increased by a factor of 10. (B) The simulation cases B1–3 are highlighted
against the other simulation cases. All of the cases are very similar to case A1.
(C) The simulation cases C1–4 are highlighted against the other simulation
cases. In two of them dextran reaches the 2.5mm point within 5min after the
injection, while the remaining two cases take up to 2min longer.
this phenomenon Supplementary Figure 3 includes a dextran
concentration level of 0.1 (0.01% of the initial concentration).
It shows that dextran travels in a continuous stream to the
surface of the brain. We observe two disconnected parts of
dextran concentration because the stream between is below
the detection level. In both cases C3 and C4 perivascular
drainage is slowed down enough such that diffusion remains
the dominant mechanism at that time point. This can also
be seen in Figure 4 as up to 8 and 7min, respectively, the
curves of C3 and A1 and C4 and A2 are almost identical. At
30min after the injection all cases in group C show a dextran
concentration above the detection level at the surface of the
brain (Supplementary Figure 1). While in case C4 this is due
to the increased diffusion coefficient for cases C1–3 we observe
the same disconnected smaller area of dextran as in case C1 at
5min after the end of the injection. This shows that perivascular
drainage has acted here as the main driving mechanism for solute
drainage.
The simulations on the sagittal slice of the mouse brain
have in general revealed very similar results as compared to
the coronal slice (Supplementary Figures 4, 5 and Figure 5).
The results for case group A are almost entirely identical,
but dextran spreads slightly further within 5min as Table 5
reveals. From Supplementary Figure 4 it appears that in case C1
dextran does not reach the 2.5 mmmark within 5min. However,
from both Table 5 and Figure 5 we can conclude that dextran
does reach the distance mark within 5min. To explain this
Supplementary Figure 3 includes the concentration level 0.1.
This figure reveals that in general dextran is spreading far away
from the injection site and that C1 in Supplementary Figure 4
is similar to C1 in Supplementary Figure 5. In the sagittal slice,
however, second area of dextran distribution above the detection
limit is too small to observe in the figure. The results for the
remaining cases of group C are analogous to the same cases in
the coronal slice.
The Péclet numbers Pe of the simulation cases show that there
appears to be a critical value, at which point the convective forces
over the diffusive forces are strong enough to drive flow in the
required time frame.
While the results of this study are in close agreement with
our hypothesis of the necessity of perivascular drainage as the
main mechanism for solute drainage in the brain there are some
limitations to this study. The first limitation is the use of 2D
simulations instead of 3D simulations. It was expected that,
qualitatively, no additional information would be gained from
using 3D over 2D simulations. This is confirmed by our results,
which match those of the experiments conducted in Carare
et al. (2008) very closely. Therefore, it was concluded that the
advantages of requiring much smaller meshes for the simulations
and therefore much less computation time weigh much more
heavily against the most likely very small gain in accuracy of the
results. Another limitation of this study is the implementation of
the perivascular drainage process as a straight path in the positive
x-direction for the coronal slice and in the positive z-direction
for the sagittal slice. In reality the perivascular drainage follow
the cerebral vasculature. To accurately represent perivascular
drainage the whole cerebral vasculature would have to be
modeled. As with the decision of using 2D over 3D simulations
the decision of how to implement this process was made by
looking at the information gain of a more complex model, which
would require a much higher computational effort, compared to
a simpler model. Based on this it was deemed legitimate to omit
an explicit implementation of the perivascular drainage pathways
and instead rely on this “observed velocity” along a straight line.
Lastly we note that we have focussed exclusively on transport
along basement membranes of capillaries and arteries as we study
the clearance of solutes from the parenchyma. There is also a
much wider field of study of how CSF communicates with the
parenchyma and it remains to be seen to what extent the two
systems interact with each other (Iliff et al., 2012, 2013).
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5. CONCLUSION AND RELEVANCE FOR
ALZHEIMER’S DISEASE
We have established by a computational model that the rapid
elimination of solutes from the central gray matter regions to
the surface of the mouse brain is not due to diffusion alone but
involves a combination of diffusion and bulk flow along basement
membranes in the walls of capillaries and arteries. These results
will help to establish the dynamics of periarterial lymphatic
drainage that fails with age and AD. Furthermore, periarterial
lymphatic drainage is relevant to recent trials of immunotherapy
for AD in which insoluble plaques of Aβ are eliminated following
the active or passive immunization of patients against Aβ (Nicoll
et al., 2003). Despite removal of Aβ from brain parenchyma,
however, there is a significant increase in the severity of
CAA (Sakai et al., 2014), suggesting that Aβ is removed from
the brain parenchyma but becomes entrapped in the ageing
periarterial lymphatic drainage pathways. Whether this is due to
the increased volume of Aβ passing into the lymphatic drainage
pathways or whether it is due to the pathways themselves being
blocked by immune complexes (Carare et al., 2013) has not been
resolved. Understanding the dynamics of periarterial lymphatic
drainage the brain will help to resolve questions related not
only to the pathogenesis of AD, but also to questions related to
immunotherapy.
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Supplementary Figure 1 | Distribution of dextran 5min after the injection
(coronal slice). The concentration levels have been dedimensionalized using the
minimum detection level of 0.1% of the injection concentration. Cases (A1–3)
consider diffusion only with different diffusion coefficients. Cases (B1–3) consider
the effect of bulk flow using the initial diffusion coefficent D∗. Cases (C1–4) include
a convective solute transport via perivascular drainage.
Supplementary Figure 2 | Distribution of dextran 30min after the injection
(coronal slice). The concentration levels have been dedimensionalized using the
minimum detection level of 0.1% of the injection concentration. Cases (A1–3)
consider diffusion only with different diffusion coefficients. Cases (B1–3) consider
the effect of bulk flow using the initial diffusion coefficient D∗. Cases (C1–4) include
a convective solute transport via perivascular drainage.
Supplementary Figure 3 | Distribution of dextran 5min after the injection
(sagittal slice). The concentration levels have been dedimensionalized using the
minimum detection level of 0.1% of the injection concentration. Cases (A1–3)
consider diffusion only with different diffusion coefficients. Cases (B1–3) consider
the effect of bulk flow using the initial diffusion coefficient D∗. Cases (C1–4) include
a convective solute transport via perivascular drainage.
Supplementary Figure 4 | Distribution of dextran 30min after the injection
(sagittal slice). The concentration levels have been dedimensionalized using the
minimum detection level of 0.1% of the injection concentration. Cases (A1–3)
consider diffusion only with different diffusion coefficients. Cases (B1–3) consider
the effect of bulk flow using the initial diffusion coefficient D∗. Cases (C1–4) include
a convective solute transport via perivascular drainage.
Supplementary Figure 5 | Distribution of dextran 5min after the injection
in case C1 in both slices. The lowest contour has been extended to include a
level of 0.1, showing how dextran spreads in the brain.
AUTHOR NOTE
All data supporting this study are openly available from the
University of Southampton repository at http://dx.doi.org/10.
5258/SOTON/386692.
REFERENCES
Abbott, N. J. (2004). Evidence for bulk flow of brain interstitial fluid:
significance for physiology and pathology. Neurochem. Int. 45, 545–552. doi:
10.1016/j.neuint.2003.11.006
Carare, R. O., Bernardes-Silva, M., Newman, T. A., Page, A. M., Nicoll,
J. A. R., Perry, V. H., et al. (2008). Solutes, but not cells, drain from
the brain parenchyma along basement membranes of capillaries and
arteries: significance for cerebral amyloid angiopathy and neuroimmunology.
Neuropathol. Appl. Neurobiol. 34, 131–144. doi: 10.1111/j.1365-2990.2007.
00926.x
Carare, R. O., Hawkes, C. A., Jeffrey, M., Kalaria, R. N., and Weller, R. O.
(2013). Review: cerebral amyloid angiopathy, prion angiopathy, CADASIL
and the spectrum of protein elimination failure angiopathies (PEFA) in
neurodegenerative disease with a focus on therapy. Neuropathol. Appl.
Neurobiol. 39, 593–611. doi: 10.1111/nan.12042
Cserr, H., and Ostrach, L. H. (1974). Bulk flow of interstitial fluid after intracranial
injection of Blue Dextran 2000. Exp. Neurol. 45, 50–60.
Cserr, H. F., Cooper, D. N., and Milhorat, T. H. (1977). Flow of cerebral interstitial
fluid as indicated by the removal of extracellular markers from rat caudate
nucleus. Exp. Eye Res. 25, 461–473.
Cserr, H. F., Cooper, D. N., Suri, P. K., and Patlak, C. S. (1981). Eﬄux of
radiolabeled polyethylene glycols and albumin from rat brain. Am. J. Physiol.
Renal Physiol. 240, F319–F328.
Deane, R., Wu, Z., Sagare, A., Davis, J., Yan, S. D., Hamm, K., et al.
(2004). LRP/Amyloid β-peptide interaction mediates differential brain
eﬄux of Aβ isoforms. Neuron 43, 333–344. doi: 10.1016/j.neuron.2004.
07.017
Duyckaerts, C., and Dickinson, D. W. (2011). “Neuropathology of Alzheimer’s
disesase and its variants,” in Neurodegeneration: The Molecular Pathology of
Dementia and Movement Disorders, 2nd Edn, eds D. W. Dickinson and R. O.
Weller (Oxford: Wiley-Blackwell), 62–91.
Frontiers in Aging Neuroscience | www.frontiersin.org 10 February 2016 | Volume 8 | Article 18
Diem et al. Modeling Periarterial Clearance of Aβ
Foley, C., Nishimura, N., Neeves, K., Schaffer, C., and Olbricht, W. L. (2012).
Real-time imaging of perivascular transport of nanoparticles during convection
enhanced delivery in the rat cortex. Ann. Biomed. Eng. 40, 292–303. doi:
10.1007/s10439-011-0440-0
Groothuis, D. R., Vavra, M. W., Schlageter, K. E., Kang, E. W.-Y., Itskovich,
A. C., Hertzler, S., et al. (2007). Eﬄux of drugs and solutes from
brain: the interactive roles of diffusional transcapillary transport, bulk flow
and capillary transporters. J. Cereb. Blood Flow Metab. 27, 43–56. doi:
10.1038/sj.jcbfm.9600315
Hawkes, C. A., Härtig, W., Kacza, J., Schliebs, R., Weller, R. O., Nicoll, J. A., et
al. (2011). Perivascular drainage of solutes is impaired in the ageing mouse
brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol.
121, 431–443. doi: 10.1007/s00401-011-0801-7
Iliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., et al. (2012).
A paravascular pathway facilitates CSF flow through the brain parenchyma
and the clearance of interstitial solutes, including amyloid β . Sci. Transl. Med.
4:147ra111. doi: 10.1126/scitranslmed.3003748
Iliff, J. J., Wang, M., Zeppenfeld, D. M., Venkataraman, A., Plog, B. A., Liao, Y.,
et al. (2013). Cerebral arterial pulsation drives paravascular CSF-interstitial
fluid exchange in the murine brain. J. Neurosci. 33, 18190–18199. doi:
10.1523/JNEUROSCI.1592-13.2013
Ito, S., Matsumiya, K., Ohtsuki, S., Kamiie, J., and Terasaki, T. (2013).
Contributions of degradation and brain-to-blood elimination across the
bloodbrain barrier to cerebral clearance of human amyloid-β peptide(1-
40) in mouse brain. J. Cereb. Blood Flow Metab. 33, 1770–1777. doi:
10.1038/jcbfm.2013.125
Lein, E. S., Hawrylycz, M. J., Ao, N., Ayres, M., Bensinger, A., Bernard, A., et al.
(2007). Genome-wide atlas of gene expression in the adult mouse brain. Nature
445, 168–176. doi: 10.1038/nature05453
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., and Love, S. (2011). Aβ-degrading
enzymes: potential for treatment of Alzheimer disease. J. Neuropathol. Exp.
Neurol. 70, 944–959. doi: 10.1097/NEN.0b013e3182345e46
Nicholson, C. (2001). Diffusion and related transport mechanisms in brain tissue.
Rep. Prog. Phys. 64, 815–884. doi: 10.1088/0034-4885/64/7/202
Nicholson, C., Chen, K. C., Hrabeˇtová, S., and Tao, L. (2000). Diffusion of
molecules in brain extracellular space: theory and experiment. Prog. Brain Res.
125, 129–154. doi: 10.1016/S0079-6123(00)25007-3
Nicholson, C., and Tao, L. (1993). Hindered diffusion of high molecular weight
compounds in brain extracellularmicroenvironmentmeasured with integrative
optical imaging. Biophys. J. 65, 2277–2290.
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., and
Weller, R. O. (2003). Neuropathology of human Alzheimer disease after
immunization with amyloid-beta peptide: a case report. Nat. Med. 9, 448–452.
doi: 10.1038/nm840
Ohata, K., and Marmarou, A. (1992). Clearance of brain edema and
macromolecules through the cortical extracellular space. J. Neurosurg. 77,
387–396.
Philippoff, W. (1957). “Viscosity of liquids,” in American Institute of Physics
Handbook, ed D. E. Gray (New York, NY: McGraw-Hill Book Company),
2.165–2.169.
Rosenberg, G. A., Kyner, W. T., and Estrada, E. (1980). Bulk flow of
brain interstitial normal and hyperosmolar conditions. Am. J. Physiol. 238,
F42–F49.
Sakai, K., Boche, D., Carare, R., Johnston, D., Holmes, C., Love, S., et al.
(2014). Aβ immunotherapy for Alzheimer’s disease: effects on apoE and
cerebral vasculopathy. Acta Neuropathol. 128, 777–789. doi: 10.1007/s00401-01
4-1340-9
Syková, E., andNicholson, C. (2008). Diffusion in brain extracellular space. Physiol.
Rev. 88, 1277–1340. doi: 10.1152/physrev.00027.2007
Szentistvanyi, I., Patlak, C. S., Ellis, R. A., and Cserr, H. (1984). Drainage of
interstitial fluid from different regions of rat brain.Am. J. Physiol. Renal Physiol.
246, F835–F844.
Thorne, R. G., and Nicholson, C. (2006). In vivo diffusion analysis with quantum
dots and dextrans predicts the width of brain extracellular space. Proc. Natl.
Acad. Sci. U.S.A. 103, 5567–5572. doi: 10.1073/pnas.0509425103
Weller, R. O., Hawkes, C. A., Carare, R. O., and Hardy, J. (2015). Does the
difference between PART and Alzheimers disease lie in the age-related changes
in cerebral arteries that trigger the accumulation of Aβ and propagation of tau?
Acta Neuropathol. 129, 763–766. doi: 10.1007/s00401-015-1416-1
Weller, R. O., Subash, M., Preston, S. D., Mazanti, I., and Carare, R. O. (2008).
Perivascular drainage of amyloid-β peptides from the brain and its failure
in cerebral amyloid angiopathy and Alzheimer’s disease. Brain Pathol. 18,
253–266. doi: 10.1111/j.1750-3639.2008.00133.x
Zlokovic, B. V. (2004). Clearing amyloid through the blood-brain
barrier. J. Neurochem. 89, 807–811. doi: 10.1111/j.1471-4159.2004.
02385.x
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Diem, Tan, Bressloff, Hawkes, Morris, Weller and Carare. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Aging Neuroscience | www.frontiersin.org 11 February 2016 | Volume 8 | Article 18
